| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:1841.)
© 2001 American Heart Association, Inc.
Original Contributions |
Open-Label Dose-Titration Safety and Efficacy Study of Tizanidine Hydrochloride in the Treatment of Spasticity Associated With Chronic Stroke
From the Department of Neurology (D.A.G.), Southern Illinois University, Springfield, Ill; Departments of Neurology (D.C.G.) and Physical Medicine and Rehabilitation (M.R.), Wake Forest University, Winston-Salem, NC; Department of Neurology (A.D.), Washington University, St Louis, Mo; and Tampa Neurologic Associates (S.S.), Tampa, Fla.
Correspondence to David A. Gelber, MD, Springfield Clinic Neuroscience Institute, 455 W Carpenter, PO Box 19248, Springfield, IL 62794-9248. E-mail Dgelber{at}springfieldclinic.com
Background and Purpose—— Spasticity is a frequently observed motor impairment that develops after stroke; it can cause pain and disability in those affected. The objective of the present study was to evaluate the safety and efficacy of tizanidine, a centrally acting 
2-adrenergic agonist, in the treatment of stroke-related spasticity.
Methods—— Forty-seven patients, who were a minimum of 6 months poststroke and had significant spasticity, were studied at 4 centers. Tizanidine was administered in an open-label manner for 16 weeks, beginning at 2 mg/d and slowly titrated to a maximum of 36 mg/d. The Modified Ashworth Scale, muscle strength testing, functional assessments, and Pain and Functional Spasticity Questionnaires were administered at baseline and at 4, 8, 16, and 18 weeks (after 1 week off tizanidine).
Results—— Spasticity was significantly improved between baseline and week 16, with a decrease in total upper extremity Modified Ashworth Scale score of 2.80±0.47 (P<0.0001). No decline in strength was noted. Treatment with tizanidine resulted in a significant improvement in pain intensity (P=0.0375), quality of life (P=0.0001), and physician assessment of disability (P=0.0001). The most frequent side effects were somnolence (62%) and dizziness (32%). No serious adverse events were considered to be drug related. Ten of 47 patients (21%) were able to reach the maximum daily dosage of 36 mg.
Conclusions—— Overall, the data suggest that tizanidine is safe and efficacious in the treatment of stroke-related spasticity, preserving muscle strength while reducing muscle tone and painful spasms in affected patients.
Key Words: spasticity • stroke • tizanidine
This article has been cited by other articles:
 |
|
 |
|
  B. Bates, J. Y. Choi, P. W. Duncan, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, D. Reker, and R. Zorowitz Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive Summary Stroke, September 1, 2005; 36(9): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Duncan, R. Zorowitz, B. Bates, J. Y. Choi, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, and D. Reker Management of Adult Stroke Rehabilitation Care: A Clinical Practice Guideline Stroke, September 1, 2005; 36(9): e100 - e143. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-D. Kao, J.-B. Chang, J.-T. Chen, Z.-A. Wu, D.-E Shan, and K.-K. Liao Hypotension Due to Interaction Between Lisinopril and Tizanidine Ann. Pharmacother., November 1, 2004; 38(11): 1840 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E Gallichio Pharmacologic Management of Spasticity Following Stroke Physical Therapy, October 1, 2004; 84(10): 973 - 981. [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Nicholson Evaluation and treatment of central pain syndromes Neurology, March 9, 2004; 62(90052): S30 - 36. [Abstract] [Full Text]
|
|